Remdesivir (Veklury)
COVID-19
ApprovedCommercial
Key Facts
About Gilead Sciences
Founded in 1987, Gilead Sciences has established itself as a premier biopharmaceutical company with a strong track record of bringing transformative medicines to market. The company generates substantial revenue from its portfolio of approved drugs, particularly in HIV and hepatitis, while investing heavily in R&D to advance next-generation therapies in oncology, inflammation, and infectious diseases. With a market capitalization of over $170 billion and a diversified pipeline, Gilead continues to be a major player in the global pharmaceutical landscape.
View full company profileOther COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| mRNA-1273 (Spikevax) | Moderna | Approved |
| Investigational Oral COVID-19 Antiviral | Shionogi | Clinical |
| ZyCoV-D | Zydus Lifesciences | Approved |
| BBIBP-CorV | Sinopharm | Approved |
| SARS-CoV-2 Neutralizing Antibodies | Adaptive Biotechnologies | Discovery |
| Covovax™ | Novavax | Approved/Commercial |
| LY-CoV555 (Bamlanivimab) | AbCellera | Emergency Use Authorization (Past) |
| ARCT-154 (Bivalent) | Arcturus Therapeutics | Phase 1/2 |
| LUNAR-COV19 (ARCT-021) | Arcturus Therapeutics | Phase 1/2 |
| Paxlovid (Nirmatrelvir) Manufacturing Enzyme | Codexis | Commercial |